Importantly, sialylated O-glycopeptide for BCAN at site T590 was higher for both GBM (no CLA) and PRO subtype versus control samples, while sialylated O-glycopeptide at S625 was increased for GBM versus control samples. This evidence concerns the gene BCAN and glioblastoma.